Bioorthogonal Polymer Nanozymes for Effective Treatment of Bacterial Wound Biofilm Infections.

Authors

Cristina-Maria Hirschbiegel, Muhammad Aamir Hassan, Yagiz Anil Cicek, William Ndugire, Maged Abdelaziz, Joe Truong, Junwhee Yang, Nourina Nasim, Mathangi Shrikanth, Vincent M Rotello

Published in

ACS applied materials & interfaces. Sep 09, 2026. Epub Sep 09, 2026.

Abstract

Multidrug-resistant (MDR) bacterial infections are a rapidly emerging healthcare crisis. The challenge of MDR bacteria is further exacerbated through biofilm formation that limits effective drug penetration and hinders the ability of the host immune system to clear the infection. Cationic polymer nanoparticles carrying bioorthogonal transition-metal catalysts (polyzymes) can penetrate bacterial biofilms and locally catalyze the uncaging of antimicrobial drug derivatives, acting as an in situ bioorthogonal "drug factory". Polyzymes were designed and fabricated using an amphiphilic polymer nanoscaffold and iron(III) tetraphenyl porphyrin as the catalyst. The polyzyme bioorthogonally uncaged an azide-protected prodrug of the antimicrobial drug moxifloxacin. The efficacy of this approach was tested in vitro against an in vitro Escherichia coli (E. coli) biofilm, resulting in a ∼3.5-log10 colony-forming units (CFU/mL) reduction of bacterial load (99.99%). The polyzyme was subsequently incorporated into a thermoresponsive Poloxamer 407 hydrogel to create a wound dressing, and the localized activation of pro-moxifloxacin was tested in an in vivo E. coli wound biofilm model. The polyzyme-mediated localized activation of the prodrug was highly effective, resulting in significantly more bacterial killing compared to the free drug moxifloxacin. These results demonstrate the therapeutic potential of bioorthogonal polyzymes for treating wound biofilm infections, with enhanced local activity and improved treatment outcomes compared to standard clinical treatment methods.

PMID:
42711243
Bibliographic data and abstract were imported from PubMed on 09 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.